TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients 60-75 years of age;~* B-cell follicular NHL;~* no previous treatment;~* active disease, with rapid progression.~Exclusion Criteria:~* other cancer within 3 years of study, except carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ of the breast treated with lumpectomy;~* long-term use (\>1 month) of systemic corticosteroids;~* central nervous system involvement;~* history of significant cardiovascular disease;~* positive test result for HIV, or hepatitis B or C.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological proven, metastatic, or locally advanced and non-operable GIST~2. Measurable tumor lesions with longest diameter ≥ 20 mm using conventional techniques or ≥ 10 mm with spiral CT scan according RECIST criteria~3. C-kit (CD117) positive tumors detected immuno-histochemically and documented mutation of c-kit at any time if available~4. Patients resistant to imatinib at dose of 400 mg/day~Exclusion Criteria:~1. Patient treated for a cancer other than GIST cancer within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ~2. Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- masitinib (Type: EXPERIMENTAL): masitinib 12 mg/kg/day
- sunitinib (Type: ACTIVE_COMPARATOR): sunitinib 50 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects 18 years of age or older, with diagnosis of chronic dermatitis, able to complete the study and comply with study instructions.~* Female subjects of childbearing potential must have a negative pregnancy test. Sexually active women of childbearing potential participating in the study must have been using a medically acceptable form of contraception~Exclusion Criteria:~* Use of systemic corticosteroid and/or other prohibited medications within 4 weeks of the baseline visit.~* Use of topical corticosteroid therapy and/or other prohibited topical medications within 2 weeks prior to the baseline visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- clobetasol propionate foam (Type: EXPERIMENTAL): All subjects receive clobetasol propionate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of moderate to severe plaque psoriasis receiving etanercept treatment for a minimum duration of 1 year.~* Age ≥18 years old.~* No history of using a biological treatment, other than etanercept, for treatment of moderate to severe plaque psoriasis or any other reason.~Exclusion Criteria:~* Etanercept use for treatment moderate to severe plaque psoriasis less than 1 year duration.~* Previous use of other biological treatments for any reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with moderate to severe plaque psoriasis (Type: None): Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interventions to Increase HBV Vaccinations in Sexually Transmitted Disease (STD) Clinics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 and older males and females~* No prior self-reported history of HBV immunization or infection~* Fluent in English~* Not known to be HIV positive.~Exclusion Criteria:~* Under age 18~* Received any prior HBV vaccination~* Prior infection of Hepatitis B~* Unable to read or comprehend the English language~* HIV positive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Non-Framed-Offered (Type: EXPERIMENTAL): Non-Framed, Information Only Condition. Vaccine Offered.
- Non-Framed-Recommended (Type: EXPERIMENTAL): Non-Framed, Information Only Condition. Vaccine Recommended.
- Gain-Framed-Offered (Type: EXPERIMENTAL): Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Offered.
- Gain-Framed-Recommended (Type: EXPERIMENTAL): Gain-Framed Intervention emphasizes the benefits associated with receiving HBV vaccine. Vaccine Recommended.
- Loss-Framed-Offered (Type: EXPERIMENTAL): Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Offered.
- Loss-Framed-Recommended (Type: EXPERIMENTAL): Loss-Framed Intervention emphasizes the risks associated with not receiving HBV vaccine. Vaccine Recommended.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Achilles Pain Block

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
For patients with AT~Inclusion Criteria:~- Clinical diagnosis of chronic (\>3 months) AT, consisting of pain with pressure at the achilles tendon and report of pain that is aggravated by physical activity~Exclusion Criteria:~* History of foot or ankle surgery, bilateral lateral epicondyle tendinopathy~* Comorbidity that would be aggravated by placing hand in water (Raynaud's, thoracic outlet syndrome)~* Comorbidity (e.g. stroke, neurological disorder) that limits ability to participate in exercise~* Comorbidity (e.g. rheumatic disease, fibromyalgia) that contributes to pain with activity~* Peripheral neuropathy~* Previous adverse response to a local anesthetic injection~* Are pregnant~* Are a ballroom dancer~For control participants~Inclusion Criteria:~- Sex, Age and BMI-matched to participant with AT~Exclusion Criteria:~* No history of tendinopathy~* No condition that limited activity in the past 6 months~* History of foot or ankle surgery, bilateral lateral epicondyle tendinopathy~* Comorbidity that would be aggravated by placing hand in water (Raynaud's, thoracic outlet syndrome)~* Comorbidity (e.g. stroke, neurological disorder) that limits ability to participate in exercise~* Comorbidity (e.g. rheumatic disease, fibromyalgia) that contributes to pain with activity~* Peripheral neuropathy~* Are pregnant~* Are a ballroom dancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Group with Achilles Tendinopathy (Type: EXPERIMENTAL): Ropivacaine injection. While looking at the Achilles tendon with ultrasound, the orthopaedic physician will inject 4 mL of 0.5% ropivacaine (numbing medicine) around the area of pain. The needle may be directed just under the skin (and above the tendon) and/or deep to the tendon.
- Group without Achilles Tendinopathy (Type: NO_INTERVENTION): The control group did not receive an injection between test repetitions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gut Imaging for Function & Transit in Cystic Fibrosis Study 1

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 12 - 40 years~* Capacity to consent, or to understand the requirements of the study where parental consent is needed~* PATIENTS: confirmed diagnosis of Cystic Fibrosis, either by sweat test or genetic testing; to reduce heterogeneity, we will only enrol homozygous CF patients with the most common CFTR mutation, p.Phe508del~* CONTROLS: no clinical evidence or suspicion of Cystic Fibrosis~Exclusion Criteria:• Measurement of Forced Expiratory Volume in 1 second (FEV1) of \<40% predicted using Global Lung Initiative criteria, according to clinical records~* Contra-indication to MRI scanning, such as embedded metal, pacemaker~* Unable to stop medications directly prescribed to alter bowel habit, such as laxatives of anti-diarrhoeals, on the study day~* Previous resection of any part of the gastro-intestinal tract apart from appendicectomy or cholecystectomy. Surgical relief of distal ileal obstruction syndrome or neonatal ileus will be permitted unless clinical records show excision of intestine \>20cm in length.~* Intestinal stoma~* Diagnosis of inflammatory bowel disease or coeliac disease confirmed by biopsy~* Gastrointestinal malignancy~* Unable to comply with dietary restrictions required for the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- CF (Type: None): people with cystic fibrosis
- Control (Type: None): people without cystic fibrosis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females between 4 years to 55 years of age,~2. Thermal burns caused by fire/flame, scalds or contact,~3. Deep partial thickness (mixed deep dermal) and/or full thickness (3°) burn wounds ≥ 5% and ≤ 30% Total Body Surface Area (TBSA); all these wounds must receive study treatment,~4. At least one wound of ≥ 2% TBSA deep partial thickness and/or full thickness burn,~5. Total burn wounds ≤ 30% TBSA,~6. Signed written informed consent.~Exclusion Criteria:~1. Deep partial thickness and/or full thickness facial burn wounds, \> 0.5% TBSA; study treatment of facial burns is not allowed,~2. Study treatment of perineal and/or genital burns (A patient with these wounds may be enrolled but the wounds may not be designated as target wounds),~3. Circumferential anterior/posterior trunk full thickness fire/flame burns, \> 15% TBSA, (Circumferential is defined as encircling ≥ 80% of the trunk circumference.)~4. Pre-enrollment escharotomy,~5. Heavily contaminated burns or pre-existing infections,~6. Signs that may indicate smoke inhalation,~7. General condition of patient would contraindicate surgery,~8. Pregnant women (positive pregnancy test) or nursing mothers,~9. Poorly controlled diabetes mellitus (HbA1c\>9%),~10. Cardio-pulmonary disease (MI within 4 weeks prior to injury, pulmonary hypertension, COPD or pre-existing oxygen-dependent pulmonary diseases),~11. Pre-existing diseases which interfere with circulation (PVD, edema, lymphedema, surgery to the regional lymph nodes, obesity, varicose veins),~12. Immediate life threatening conditions (such as immuno-compromising diseases, life threatening trauma, severe pre-existing coagulation disorder, cardiovascular, liver or neoplastic disease),

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- DGD (Type: EXPERIMENTAL): None
- SOC (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent prior to performing study procedures (participants ≥ 18 years of age) or assent (participants ≥ 12 and \< 18 years of age) prior to performing study procedures. For participants ≥ 12 and \< 18 years of age, a parent or legal guardian willing and able to provide written informed consent prior to performing study procedures~* Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction (PCR) test ≤ 4 days before randomization~* Currently hospitalized and requiring medical care for COVID-19~* Peripheral capillary oxygen saturation (SpO2) \> 94% on room air at screening~* Radiographic evidence of pulmonary infiltrates~Key Exclusion Criteria:~* Participation in any other clinical trial of an experimental treatment for COVID-19~* Concurrent treatment or planned concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2~* Requiring mechanical ventilation at screening~* Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5 X upper limit of normal (ULN)~* Creatinine clearance \< 50 mL/min using the Cockcroft-Gault formula for participants ≥ 18 years of age {Cockcroft 1976} and Schwartz Formula for participants \< 18 years of age~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A: Remdesivir (RDV), 5 Days (Type: EXPERIMENTAL): Participants will receive continued standard of care (SOC) therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, and 5.
- Part A: Remdesivir, 10 Days (Type: EXPERIMENTAL): Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.
- Part A: SOC Therapy (Type: ACTIVE_COMPARATOR): Participants will receive continued standard of care therapy.
- Part B: Extension Treatment, Remdesivir 10 Days (Type: EXPERIMENTAL): Participants will receive continued standard of care therapy together with RDV 200 mg on Day 1 followed by RDV 100 mg on Days 2, 3, 4, 5, 6, 7, 8, 9, and 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ED95 of Lidocaine 1.0% for Filling the Adductor Canal

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* 18-30 years~* Men~* American Society of Anesthesiologists' class 1~* Body Mass Index 18-25~Exclusion Criteria:~* Allergy to study medication~* Earlier trauma or surgery to the lower limb~* Diabetes Mellitus - Contraindications to MRI

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- ACB with 30 ml lidocaine 1% (Type: EXPERIMENTAL): Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml.
- ACB with 25 ml lidocaine 1% (Type: EXPERIMENTAL): Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml.
- ACB with 20 ml lidocaine 1% (Type: EXPERIMENTAL): Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml.
- ACB with 15 ml lidocaine 1% (Type: EXPERIMENTAL): Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml.
- ACB with 10 ml lidocaine 1% (Type: EXPERIMENTAL): Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml.
- ACB with 5 ml lidocaine 1% (Type: EXPERIMENTAL): Procedure/Surgery: Adductor canal block with lidocaine 1% The Continual Reassessment Method is used to calculate the dose level consecutively for every new cohort (2 subjects) in the study.~Possible dose levels are: 5, 10, 15, 20, 25 and 30 ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) greater than or equal to (\>=) 35 to less than or equal to (\<=) 50 kilogram per square meter (kg/m\^2) at the screening visit~* Stable weight (that is, change of \<= 5 percent \[%\] within 12 weeks before screening based on medical history)~* Women must be either: (a) Postmenopausal, or (b) Permanently sterilized or otherwise be incapable of pregnancy, or (c) Heterosexually active and practicing a highly effective method of birth control, or (d) Not heterosexually active~* Woman of childbearing potential have a negative pregnancy test at screening~* Willing and able to adhere to specific the prohibitions and restrictions~Exclusion Criteria:~* History of obesity with a known secondary cause (for example, Cushing's disease/syndrome)~* History of Type 1 diabetes mellitus, Type 2 diabetes mellitus (T2DM), diabetic ketoacidosis (DKA), pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy~* Has a Hemoglobin A1c (HbA1c) of \>= 6.5% or fasting plasma glucose (FPG) \>= 126 milligrams per deciliter (mg/dL) (\>= 7.0 millimoles per liter \[mmol/L\]) at screening~* Screening calcitonin of \>= 50 picograms per milliliter (pg/mL) personal history or family history of medullary thyroid cancer, or of multiple endocrine neoplasia syndrome type 2 (MEN 2), regardless of time prior to screening~* History of glucagonoma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Double-Blind: JNJ-64565111 Dose Level 1 (Type: EXPERIMENTAL): Participants will receive a JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 26-week treatment phase.
- Double-Blind: JNJ-64565111 Dose Level 2 (Type: EXPERIMENTAL): Participants will receive a JNJ-64565111 Dose Level 2 SC once-weekly for 26-week treatment phase.
- Double-Blind: JNJ-64565111 Dose Level 3 (Type: EXPERIMENTAL): Participants will receive a JNJ-64565111 Dose Level 3 SC once-weekly for 26-week treatment phase.
- Double-Blind: Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 26-week treatment phase.
- Open-Label: 3.0 milligram (mg) Liraglutide (Type: ACTIVE_COMPARATOR): Participant will receive once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg. The participants will receive liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1. Participants will be instructed to increase the dose of liraglutide by 0.6 mg dose increment every 7 days, up to the full dosage of 3.0 mg by Week 5. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete